Novel therapeutic approaches to target neurodegeneration
British Journal of Pharmacology · 2023-07 · 180 (13) · 1651-1673
DOI: 10.1111/bph.16078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 26.04.2023. Verfasst von Alerie G de la Fuente und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain. Hauptthemen laut MEDLINE: Protein Aggregates, Neurodegenerative Diseases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Wellcome Trust, Ministero dell'Università e della Ricerca.
Abstract (Originalsprache)
Ageing is the main risk factor common to most primary neurodegenerative disorders. Indeed, age‐related brain alterations have been long considered to predispose to neurodegeneration. Although protein misfolding and the accumulation of toxic protein aggregates have been considered as causative events in neurodegeneration, several other biological pathways affected by brain ageing also contribute to pathogenesis. Here, we discuss the evidence showing the involvement of the mechanisms controlling neuronal structure, gene expression, autophagy, cell metabolism and neuroinflammation in the onset and progression of neurodegenerative disorders. Furthermore, we review the therapeutic strategies currently under development or as future approaches designed to normalize these pathways, which may then increase brain resilience to cope with toxic protein species. In addition to therapies targeting the insoluble protein aggregates specifically associated with each neurodegenerative disorder, these novel pharmacological approaches may be part of combined therapies designed to rescue brain function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
- Instituto de Neurociencias CSIC-UMH, Alicante, Spain.
- Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
- Institute of Molecular Biology, Leopold-Franzens-Universität Innsbruck, Innsbruck, Austria.
- Department of Neurosciences, University of California San Diego, La Jolla, California, USA.
ORCID-Profile: Alerie G de la Fuente, Silvia Pelucchi, Jerome Mertens, Monica Di Luca, Daniela Mauceri, Elena Marcello
Förderung
- NIA NIH HHS
- Wellcome Trust
- Ministero dell'Università e della Ricerca
- Fondazione Cariplo
- Alzheimer Forschung Initiative
- Chica and Heinz Schaller Foundation
- Instituto de Salud Carlos III
- BrightFocus Foundation
Zitieren
APA
de la Fuente, A. G., Pelucchi, S., Mertens, J., Di Luca, M., Mauceri, D., & Marcello, E. (2023). Novel therapeutic approaches to target neurodegeneration. British Journal of Pharmacology, 180(13), 1651-1673. https://doi.org/10.1111/bph.16078
Vancouver
de la Fuente AG, Pelucchi S, Mertens J, Di Luca M, Mauceri D, Marcello E. Novel therapeutic approaches to target neurodegeneration. British Journal of Pharmacology. 2023;180(13):1651-1673. doi:10.1111/bph.16078
BibTeX
@article{delaFuente2023,
author = {de la Fuente, Alerie G and Pelucchi, Silvia and Mertens, Jerome and Di Luca, Monica and Mauceri, Daniela and Marcello, Elena},
title = {Novel therapeutic approaches to target neurodegeneration},
journal = {British Journal of Pharmacology},
year = {2023},
volume = {180},
number = {13},
pages = {1651--1673},
doi = {10.1111/bph.16078}
}
EUVIMED